Faricimabum (faricimab) is a bispecific antibody developed as an active pharmaceutical ingredient for use in the manufacture of therapies targeting retinal vascular diseases. It is designed to simultaneously bind to and inhibit both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2), addressing pathways involved in retinal neovascularization.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Faricimabum?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Vyleesi
pharmaceutical raw material
(2S)-2-[[(2S)-2-(dimethylamino)-3-methylbutanoyl]amino]-N-[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
pharmaceutical raw material
Norfentanyl
pharmaceutical raw material
Deucravacitinib
pharmaceutical raw material
The international HS code for Faricimabum (CAS 1607793-29-2) is 3002.13.
3002.13
3002 13 00
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
[6-chloro-1-[2-(dimethylamino)ethyl]-2,3-dihydroindol-3-yl]-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylmethanone
DRMVDBATNZBNEB-UHFFFAOYSA-N
CN(C)CCN1CC(C2=C1C=C(C=C2)Cl)C(=O)N3CCC4(CC3)C5=CC=CC=C5CO4
Sourcing Faricimabum?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.